NCT07087158 2025-07-28
A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma
Imbioray (Hangzhou) Biomedicine Co., Ltd.
Phase 2 Not yet recruiting
Clinical Trials
31 trialsNCT01147822 2025-03-28
Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma
Novartis
Phase 2 Completed
NCT01767636 2025-03-03
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer
Mayo Clinic
Phase 2 Completed
NCT03200717 2023-08-21
IO-PAZ
Novartis
Phase 2 Completed
NCT01157091 2022-06-08
Pazopanib Hydrochloride in Treating Patients With Stage IV Kidney Cancer
City of Hope Medical Center
Phase 2 Completed
NCT01664182 2022-06-07
Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT03334409 2022-03-31
Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery
Academic and Community Cancer Research United
Phase 2 Terminated
NCT01566747 2021-12-23
Second-line Pazopanib Renal Cell Carcinoma (RCC) Study. CTRIAL-IE (ICORG) 10-01, V5
Cancer Trials Ireland
Phase 2 Completed
NCT01392183 2021-09-20
Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02959554 2021-09-08
NIVOSWITCH
AIO-Studien-gGmbH
Phase 2 Terminated
NCT01743482 2021-05-14
Pazotest-01
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Completed
NCT02960906 2021-04-26
BIONIKK
Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
Phase 2 Completed
NCT04462445 2020-07-10
PIPELINE
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Completed
NCT01392352 2020-02-13
HYPAZ
Cambridge University Hospitals NHS Foundation Trust
Phase 2 Terminated
NCT03379012 2019-10-22
FARETES
Kidney Cancer Research Bureau
Phase 2 Completed
NCT01731158 2019-02-06
BERAT
Central European Society for Anticancer Drug Research
Phase 2 Completed
NCT01832259 2018-12-12
A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection
University of Utah
Phase 2 Completed
NCT02560012 2018-10-12
Personalized Targeted Inhibitors Treatment in Renal Cell Cancer
The University of Texas Health Science Center, Houston
Phase 2 Terminated
NCT01158521 2018-09-12
Pazopanib Hydrochloride Before Surgery in Treating Patients With Kidney Cancer
Case Comprehensive Cancer Center
Phase 2 Completed
NCT01361113 2018-04-25
Neoadjuvant Pazopanib in Renal Cell Carcinoma
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT01622660 2017-08-22
Gemcitabine and Pazopanib in Chemotherapy Naïve Patients With Advanced/Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Chemotherapy
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated
NCT02089802 2017-08-18
OPERA
Interessenverband zur Qualitätssicherung der Arbeit niedergelassener Uro-Onkologen in Deutschland e.
Phase 2 Terminated
NCT01108055 2017-06-09
Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer
Stanford University
Phase 2 Completed
NCT00256880 2017-01-18
Pazopanib (GW786034) In Subjects With Relapsed Or Refractory Multiple Myeloma
GlaxoSmithKline
Phase 2 Completed
NCT00454571 2016-02-10
Pazopanib Hydrochloride After Leuprolide Acetate or Goserelin Acetate in Treating Patients With Relapsed Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00731211 2015-05-20
Pazopanib in Previously Treated Patients With Metastatic Renal Cell Carcinoma
SCRI Development Innovations, LLC
Phase 2 Completed
NCT02324803 2014-12-24
Phase II Study of Pazopanib as Second-line Treatment After Sunitinib in mRCC Patients
Southern China Urology Cancer Consortium
Phase 2 Unknown
NCT01408004 2014-07-16
ROPETAR
Netherlands Working Group on Immunotherapy of Oncology
Phase 2 Completed
NCT00471536 2014-05-30
Pazopanib in Treating Patients With Metastatic Urothelial Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01577784 2014-03-12
Pazopanib in Second-line Therapy in Renal Cell Carcinoma
Associació per a la Recerca Oncologica, Spain
Phase 2 Unknown
NCT00945477 2013-11-18
Pazopanib as Second Line Therapy in Patients With Metastatic Prostate Cancer Refractory to Total Androgen Blockade
Illinois CancerCare, P.C.
Phase 2 Terminated